THOUSAND OAKS, Calif., Sept. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral...
↧
Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
↧